Clinical Trials Sponsored by InnoVec Biotherapeutics Inc.

Total 217 results

SAb Biotherapeutics, Inc.

Active, not recruiting

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

Influenza | Influenza Type B | Influenza Type A

United States
Conjupro Biotherapeutics, Inc.

Withdrawn

Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers

Asthma

United States
Allgenesis Biotherapeutics Inc.

Completed

A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia (SURPH)

Pterygium

Australia
Stealth BioTherapeutics Inc.

Completed

A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure

Heart Failure

Spain, Hungary, Netherlands, United Kingdom, Serbia, France, Latvia, Belgium, Bulgaria, Poland
Stealth BioTherapeutics Inc.

Completed

Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study (MMPOWER-2)

Primary Mitochondrial Disease

United States
CardioVascular BioTherapeutics, Inc.

Unknown

FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease

Peripheral Arterial Disease | Intermittent Claudication | Stenosis

United States
Asterias Biotherapeutics, Inc.

Completed

A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States
Iovance Biotherapeutics, Inc.

Withdrawn

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

United States
REMD Biotherapeutics, Inc.

Completed

Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus

Diabetes | Type 2 Diabetes Mellitus

United States
Stealth BioTherapeutics Inc.

Completed

A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function

Normal and Impaired Renal Function

United States
Stealth BioTherapeutics Inc.

Completed

A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure

Congestive Heart Failure

Bulgaria
Stealth BioTherapeutics Inc.

Completed

A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)

Healthy

United States
Nitric BioTherapeutics, Inc

Completed

A Dose Response Trial to Evaluate Clinical and Mycological Effect of Nitric Oxide in Subjects With Tinea Pedis

Tinea Pedis

Canada, Saint Kitts and Nevis
Nitric BioTherapeutics, Inc

Completed

Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail

Onychomycosis

United States
Stealth BioTherapeutics Inc.

Completed

The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking

Healthy Volunteers

United States
Nitric BioTherapeutics, Inc

Terminated

Reduction of Bacteria in MRSA Positive Ulcers

Leg Ulcer | Pressure Ulcer

Canada
Stealth BioTherapeutics Inc.

Completed

Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults

Healthy

United States
Pfizer
Innovex, Inc

Completed

Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg

Rheumatoid Arthritis

Luxembourg
SAb Biotherapeutics, Inc.
Hvivo

Active, not recruiting

Study of SAB-176 in Healthy Adult Participants

Influenza A H1N1

United Kingdom
Jennerex Biotherapeutics

Completed

A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Korea, Republic of
Allgenesis Biotherapeutics Inc.
ORA, Inc.

Completed

A Study of AG-80308 in Dry Eye Patients

Dry Eye Disease

United States
Bridge Biotherapeutics, Inc.
Covance

Completed

Efficacy and Safety of Orally Administered BBT-401-1S in Subjects With Ulcerative Colitis

Ulcerative Colitis

United States, Korea, Republic of, Poland, Ukraine
Bridge Biotherapeutics, Inc.
Covance

Terminated

Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis

Ulcerative Colitis

New Zealand
Jennerex Biotherapeutics

Completed

A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma

Carcinoma, Hepatocellular

United States, Korea, Republic of, Canada
Sensei Biotherapeutics, Inc.
Accelovance

Completed

Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients

Prostate Cancer

United States
Jennerex Biotherapeutics

Completed

A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer (FLASH)

Hepatocellular Carinoma

United States, Korea, Republic of, Spain
Jennerex Biotherapeutics

Completed

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors

Melanoma | Renal Cell Carcinoma | Lung Cancer | Squamous Cell Carcinoma of the Head and Neck

United States, Canada
Steminent US, Inc.

Not yet recruiting

Stemchymal® for Polyglutamine Spinocerebellar Ataxia

Spinocerebellar Ataxias
Sensei Biotherapeutics, Inc.
Regeneron Pharmaceuticals

Recruiting

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Melanoma | Sarcoma | Kidney Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Bladder Cancer | Cervix Cancer | Advanced Solid Tumor | Advanced Cancer | Colon Cancer | Thyroid Cancer | Solid Tumor... and other conditions

United States
Immorna Biotherapeutics, Inc.
ICON plc

Recruiting

A Phase 1/2 Study to Assess the Safety and Immunogenicity of JCXH-221, an mRNA-based Broadly Protective COVID-19 Vaccine

COVID-19 | Infectious Disease

United States
A2 Biotherapeutics Inc.
Tempus AI

Recruiting

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (EVEREST-1)

Cancer | Colorectal Neoplasms | Colorectal Cancer | Pancreatic Neoplasms | Pancreatic Cancer | NSCLC | Solid Tumor | Non Small Cell Lung Cancer | Colorectal Cancer Metastatic | Pancreas Cancer | Colorectal Adenocarcinoma | Solid Tumor, Adult | CRC | NSCLC, Recurrent | Non Small Cell Lung Cancer Recurrent | Non-Small Cell...

United States
A2 Biotherapeutics Inc.
Tempus AI

Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing (BASECAMP-1)

Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Neoplasms | Ovarian Cancer | NSCLC | Non Small Cell Lung Cancer | Mesothelioma | Mesothelioma, Malignant | Pancreas Cancer | Ovarian Carcinoma | Solid Tumor, Adult | CRC | Mesothelioma; Lung

United States
Immorna Biotherapeutics, Inc.
ICON plc

Active, not recruiting

A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine (JCXH-105)

Infectious Disease | Shingles | Herpes Zoster (HZ)

United States
Affimed GmbH
Artiva Biotherapeutics, Inc.

Recruiting

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203)

Peripheral T Cell Lymphoma | Relapsed or Refractory Hodgkin Lymphoma

United States
A2 Biotherapeutics Inc.
Tempus AI

Recruiting

A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2)

Cancer | Colorectal Cancer | Ovarian Neoplasms | Ovarian Cancer | NSCLC | Lung Cancer | Rectal Cancer | Non Small Cell Lung Cancer | Mesothelioma | Mesothelioma, Malignant | Colon Cancer | Pancreas Cancer | Colorectal Adenocarcinoma | Solid Tumor, Adult | CRC | Pancreatic Neoplasm | Ovary Cancer | NSCLC, Recurrent | Non-Small Cell... and other conditions

United States
Shanghai Pharma Biotherapeutics USA Inc.

Recruiting

Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

Liposarcoma, Dedifferentiated

United States
Shanghai Pharma Biotherapeutics USA Inc.

Recruiting

Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis

Ulcerative Colitis

United States
Yale University
Iovance Biotherapeutics, Inc.

Completed

Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer

Metastatic Triple Negative Breast Cancer

United States
Jennerex Biotherapeutics
Transgene

Completed

Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

Colorectal Carcinoma | CRC

Canada, United States, France
Innovus Pharmaceuticals, Inc.

Unknown

An Open Label Study to Assess the Effect of Euryco-10® Oral Dietary Supplement in Senior Men

Healthy Aging

United States
Innovus Pharmaceuticals, Inc.

Unknown

A Study to Evaluate the Effect and Tolerance of Musclin™ (Thymol) in Healthy Subjects

Healthy Volunteers

United States
Allgenesis Biotherapeutics Inc.
Lexitas Pharma Services, Inc.

Active, not recruiting

AG-73305 Single Ascending Dose Cohort Study in DME

Diabetic Macular Edema

United States
Bridge Biotherapeutics, Inc.
KCRN Research, LLC

Completed

First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers

Ulcerative Colitis

United States
Loma Linda University
Nitric BioTherapeutics, Inc

Terminated

Topical Nitric Oxide Trial in Chronic Non-Healing Wounds

Chronic Ulcer of Lower Extremity

United States
Innovo Therapeutics, Inc.

Recruiting

Ointment to Prevent Scar After Thyroidectomy

Scar

Korea, Republic of
Innovo Therapeutics, Inc.

Completed

First in Human, Single Ascending Dose Study

Ulcerative Colitis

Korea, Republic of
Innova Vascular, Inc.

Not yet recruiting

Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST) (TRUST)

Pulmonary Embolism
Bolt Biotherapeutics, Inc.
Bristol-Myers Squibb

Active, not recruiting

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

HER2-positive Breast Cancer | HER2-positive Colorectal Cancer | HER2-positive Solid Tumors | HER2-positive Gastroesophageal Cancer | HER2-positive Endometrial Cancer

France, United States, Spain, Korea, Republic of, Italy
Bolt Biotherapeutics, Inc.
Hoffmann-La Roche

Active, not recruiting

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Metastatic Breast Cancer | HER2-positive Breast Cancer

Spain, United States, Italy
Bridge Biotherapeutics, Inc.
KCRN Research, LLC

Terminated

Efficacy and Safety of BBT-401-1S in Ulcerative Colitis

Ulcerative Colitis

United States

Clinical Trials Sponsored by InnoVec Biotherapeutics Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations